Posted byOrthoEx Posted in
Posted on Mar 01, 2018

After the success of the European program REBORNE (FP7) focused on safety and efficacy of the Biomatlante matrix combined with autologous bone marrow expanded mesenchymal stem cells (MSC), MBCP+™*, made from our well-known MBCP Technology, was confirmed as the adapted matrix for tissue engineering and chosen for 2 new European research programs (H2020): MAXIBONE and ORTHOUNION.

The current challenge is to compare the clinical performances of this Advanced Therapy Medicinal Product (MBCP+™/MSC) with autograft, considered as the gold-standard for bone reconstruction: MAXIBONE (150 patients) for bone augmentation in maxillofacial surgery before dental implant placement and ORTHOUNION (about 100 patients) focused on non-union after long bone fractures.

BIOMATLANTE will showcase its technology at the American Academy of Orthopaedic Surgeons (AAOS) Congress, held 6-10 March 2018 in New Orleans, USA.

About BIOMATLANTE, experts in bone regeneration 
Based near Nantes, France, Biomatlante specializes in synthetic biomaterials for bone regeneration and is a world leader in bone graft technologies, selling its products in over 50 countries. Biomatlante’s products are routinely used in orthopedics and trauma surgery, in spine and dental surgery. BIOMATLANTE strives to integrate a strategy of strong innovation and product development required to meet and exceed the needs of today’s market. Our R&D collaborates closely with universities and research centers across the world, bringing together competences in innovation, technological transfers of new biomaterials, surgical technologies and providing the intellectual protection required to foster long-term projects.

About MBCP™ Technology*, worldwide reference in synthetic bone graft 
The unique manufacturing process developed by BIOMATLANTE confers its core MBCP biphasic HA/ ß-TCP technology unique properties for hard tissue regeneration. Its micro-macroporous structure mimics that of human bone and provides an ideal osteogenic matrix for bone regeneration in general and tissue engineering in particular.

About REBORNE, Regenerating Bone Defects using New biomedical Engineering approaches 
The objective of REBORNE is to develop new biomaterials that stimulate bone tissue formation with a view to correcting bone regeneration defects in orthopedic and maxillofacial surgery. Biomaterials, combined with the use of stem cells, are interesting alternatives to biological grafts.

About MAXIBONE, Personalized maxillofacial bone regeneration 
This European project aims at performing a multicenter clinical trial on 150 patients for bone augmentation in maxillofacial surgery prior to dental implants with autologous bone marrow expanded mesenchymal stem cells and biomaterials versus autologous bone grafting. Personalized 3D printed calcium phosphate biomaterials are also developed and in the R&D workpackage, a new optimized smart scaffold for cells and drugs combination will also be tested and developed.

The “ORTHOpaedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONs” (ORTHOUNION) is a 5 years project funded with 6M EUR by the EU H2020 programme, in the topic SCI-PM-11-2016-17: Clinical research on regenerative medicine.

For further information about BIOMATLANTE and its technologies, please visit

  • This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use